Pulse Biosciences (NASDAQ:PLSE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pulse Biosciences (NASDAQ:PLSE) from a sell rating to a hold rating in a research note released on Saturday,Wall Street Zen reports.

Several other analysts also recently commented on the stock. Oppenheimer reiterated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Needham & Company LLC began coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective on the stock. Mizuho set a $45.00 target price on shares of Pulse Biosciences in a report on Monday, August 10th. Finally, Canaccord Genuity Group upped their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Pulse Biosciences Trading Up 5.8%

Shares of NASDAQ PLSE opened at $50.33 on Friday. Pulse Biosciences has a twelve month low of $12.56 and a twelve month high of $50.90. The stock has a 50 day moving average of $35.87 and a two-hundred day moving average of $27.21. The stock has a market cap of $3.48 billion, a P/E ratio of -42.65 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. As a group, research analysts predict that Pulse Biosciences will post -1.29 earnings per share for the current year.

Insider Activity

In related news, COO Liane Rae Teplitsky bought 1,036 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average price of $48.23 per share, with a total value of $49,966.28. Following the completion of the acquisition, the chief operating officer owned 1,036 shares in the company, valued at approximately $49,966.28. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 74.00% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in Pulse Biosciences in the 1st quarter valued at $323,000. Creative Planning increased its stake in Pulse Biosciences by 26.3% in the 2nd quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after buying an additional 3,951 shares during the period. Legal & General Group Plc raised its position in Pulse Biosciences by 57.7% during the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock worth $338,000 after buying an additional 8,197 shares during the last quarter. Norges Bank purchased a new position in Pulse Biosciences during the 2nd quarter worth $302,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Pulse Biosciences during the 2nd quarter worth $158,000. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.